Clinical trial · Interventional
Bergonie Institut Profiling : Fighting Cancer by Matching Molecular Alterations and Drugs in Early Phase Trials
NCT02534649CI-TRIAL-00096187BIPrecruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a biology driven, monocentric study designed to identify actionable molecular alterations in cancer patients with advanced disease. In this trial, high throughput analysis will be carried out using next generation sequencing, and immunological profiling. Patients included in the BIP study and for whom a targetable genomic alteration had been identified might be subsequently included in an early phase trials running at Institut Bergonie or another French hospital.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hematological Malignancy | Hematopoietic and Lymphoid Cell Neoplasm | PROBABILISTIC | 0.70 |
| Solid Tumor | Solid Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Newly obtained biopsy and Blood samples collection | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Experimental
- description
- Newly obtained biopsy and Blood samples collection
- interventionNames
- Procedure: Newly obtained biopsy and Blood samples collection
Primary outcomes (1)
- measure
- Proportion of patients presenting at least one genomic alteration
- timeFrame
- 1 month
- description
- The proportion of patients with advanced cancer presenting at least one genomic alteration will be described in the NGS population and reported using the proportion. The 95% two-sided confidence limits (95%CI) will be provided for the calculated rate (binomial law).
Secondary outcomes (3)
- measure
- - Utilization rates of molecular profiling information (including utilization of information for standard regimens or clinical trials of molecularly targeted therapies)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age ≥ 18 years, 2. Histology: solid malignant tumor or hematological malignancy, 3. Deleted MSA9 4. Deleted MSA9, 5. Deleted MSA9, 6. Deleted MSA9, 7. Patient with a social security in compliance with the French law relating to biomedical research (Article L.1121-11 of French Public Health Code), 8. Voluntary signed and dated written informed consent prior to any study specific procedure. Exclusion Criteria: 1. Deleted MSA9 2. Deleted MSA9 3. Deleted MSA9 4. Deleted MSA9 5. Deleted MSA9 6. Deleted MSA9 7. Deleted MSA9 8. Deleted MSA9 9. Individuals deprived of liberty or placed under guardianship 10. Pregnant or breast feeding women, 11. Previous enrolment in the present study.
References
Publications (1)
- DERIVEDGuegan JP, Peyraud F, Dadone-Montaudie B, Teyssonneau D, Palmieri LJ, Clot E, Cousin S, Roubaud G, Cabart M, Leroy L, Lebreton C, Rey C, Lara O, Odin O, Brunet M, Vanhersecke L, Gruyters EO, Achour I, Belcaid L, Le Moulec S, Grellety T, Bessede A, Italiano A. Analysis of PD1, LAG3, TIGIT, and TIM3 expression in human lung adenocarcinoma reveals a 25-gene signature predicting immunotherapy response. Cell Rep Med. 2024 Dec 17;5(12):101831. doi: 10.1016/j.xcrm.2024.101831. Epub 2024 Nov 25. PMID 39591972